IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i4p3176-d1065268.html
   My bibliography  Save this article

Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis

Author

Listed:
  • Siwaporn Niyomsri

    (Department of Medical Services, Ministry of Public Health, Nonthaburi 11000, Thailand
    Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK)

  • Mantiwee Nimworapan

    (Pharmaceutical Care Training Center (PCTC), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
    Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand)

  • Wanwarang Wongcharoen

    (Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand)

  • Piyameth Dilokthornsakul

    (Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand)

Abstract

Background: Direct oral anticoagulants (DOACs) have been used for venous thromboembolism (VTE) in Thailand. However, they have not been listed in the National List of Essential Medicines (NLEM). A cost-effectiveness analysis is needed to aid policymakers in deciding whether DOACs should be listed in the NLEM. This study aimed to assess the cost-effectiveness of DOACs for patients with VTE in Thailand. Methods: A cohort-based state transition model was constructed from a societal perspective with a lifetime horizon. All available DOACs, including apixaban, rivaroxaban, edoxaban, and dabigatran, were compared with warfarin. A 6-month cycle length was used to capture all costs and health outcomes. The model consisted of nine health states, including VTE on treatment, VTE off treatment, recurrent VTE, clinically relevant non-major bleeding, gastrointestinal bleeding, intracranial bleeding, post-intracranial bleeding, chronic thromboembolic pulmonary hypertension, and death. All inputs were based on a comprehensive literature review. The model outcomes included total cost and quality-adjusted life-years (QALYs) with a 3% annual discount rate. A fully incremental cost-effectiveness analysis and the incremental cost-effectiveness ratio (ICER) per QALY gained were calculated at a willingness-to-pay (WTP) of THB 160,000/QALY ($5003). The robustness of the findings was assessed using deterministic and probabilistic sensitivity analyses. Results: All DOACs were associated with a decreased risk of VTE recurrence and intracranial hemorrhage. In the base-case analysis, apixaban could increase 0.16 QALYs compared with warfarin. An ICER for apixaban was 269,809 Thai baht (THB)/QALY ($8437/QALY). Rivaroxaban had a better QALY than warfarin at 0.09 QALYs with an ICER of 757,363 THB/QALY ($23,682/QALY). Edoxaban and dabigatran could also increase by 0.10 QALYs with an ICER of 709,945 THB ($22,200) and 707,145 THB ($22,122)/QALY, respectively. Our probabilistic sensitivity analyses indicated that warfarin had a 99.8% possibility of being cost-effective, while apixaban had a 0.2% possibility of being cost-effective at the current WTP. Other DOACs had no possibility of being cost-effective. Conclusions: All DOACs were not cost-effective for VTE treatment at the current WTP in Thailand. Apixaban is likely to be the best option among DOACs.

Suggested Citation

  • Siwaporn Niyomsri & Mantiwee Nimworapan & Wanwarang Wongcharoen & Piyameth Dilokthornsakul, 2023. "Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis," IJERPH, MDPI, vol. 20(4), pages 1-15, February.
    • Handle: RePEc:gam:jijerp:v:20:y:2023:i:4:p:3176-:d:1065268
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/4/3176/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/20/4/3176/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Ma, 2022. "Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 213-221, March.
    2. Thananan Rattanachotphanit & Chulaporn Limwattananon & Onanong Waleekhachonloet & Phumtham Limwattananon & Kittisak Sawanyawisuth, 2019. "Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding," PharmacoEconomics, Springer, vol. 37(2), pages 279-289, February.
    3. Piyameth Dilokthornsakul & Ratree Sawangjit & Pisit Tangkijvanich & Maneerat Chayanupatkul & Tawesak Tanwandee & Wattana Sukeepaisarnjaroen & Pajaree Sriuttha & Unchalee Permsuwan, 2022. "Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 587-596, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ghislaine van Mastrigt & Caroline van Heugten & Anne Visser-Meily & Leonarda Bremmers & Silvia Evers, 2022. "Estimating the Burden of Stroke: Two-Year Societal Costs and Generic Health-Related Quality of Life of the Restore4Stroke Cohort," IJERPH, MDPI, vol. 19(17), pages 1-15, September.
    2. Siti Norain Azahar & Saperi Sulong & Wan Asyraf Wan Zaidi & Norliza Muhammad & Yusof Kamisah & Norliana Masbah, 2022. "Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study," IJERPH, MDPI, vol. 19(3), pages 1-17, January.
    3. Yichen Zhang & Yuxuan Wei & Huangqianyu Li & Yixuan Chen & Yiran Guo & Sheng Han & Luwen Shi & Xiaodong Guan, 2022. "Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China," PharmacoEconomics, Springer, vol. 40(7), pages 715-724, July.
    4. de Melo Santos, Carlos Jefferson & Sant’Anna, Angelo Marcio Oliveira, 2024. "Evaluation of the public policy impacts on Monkeypox in Brazil," Evaluation and Program Planning, Elsevier, vol. 103(C).
    5. Susanne Mayer & Agata Łaszewska & Judit Simon, 2022. "Unit Costs in Health Economic Evaluations: Quo Vadis, Austria?," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    6. Chia-Chin Li & Ying-Chun Lin & Ji-An Liang & K. S. Clifford Chao & Te-Chun Hsia & Chun-Ru Chien, 2023. "Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review," IJERPH, MDPI, vol. 20(6), pages 1-10, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:4:p:3176-:d:1065268. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.